Answers are grounded in this paper and cite their sources.
Evaluates PD-L1/TGF-β bispecific antibody for survival in gastric cancer, suggesting potential benefits.
胃癌在中国的疾病负担居恶性肿瘤前列。免疫检查点抑制剂的引入虽改变了晚期胃癌的治疗格局,但单一阻断程序性死亡受体-1(programmed death-1, PD-1)/程序性死亡配体-1(programmed death-ligand 1, PD-L1)通路的治疗策略仍存在疗效局限及耐药难题,临床需求尚未得到充分满足。转化生长因子-β(transforming growth factor-β, TGF-β)通路在肿瘤免疫微环境中发挥关键免疫调控功能,可与PD-1/PD-L1通路协同介导肿瘤免疫逃逸,为双靶点联合干预提供了理论基础。SHR-1701(瑞拉芙普α注射液)作为全球首款获批上市的抗PD-L1/TGF-βRII双功能融合蛋白,通过同步阻断PD-L1与TGF-β双重信号通路,其III期临床研究结果显示较单纯化疗具有显著生存获益优势,且在合并肝转移、腹膜转移及弥漫型组织学类型等高危亚组中表现更为突出。本文系统梳理PD-L1/TGFβ双靶点治疗策略用于晚期胃癌的理论依据、临床证据、现存挑战及未来发展方向,以期为临床诊疗实践及后续相关研究提供参考。
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: